Navigation Links
Therapies to improve biochemical functions hold promise as treatments for autism
Date:6/2/2011

Two promising new treatments to aid people with autism have shown effectiveness in pilot studies conducted by an Arizona State University professor and private researchers.

Several studies indicate that children with autism often have abnormalities in critical biochemical functions that help maintain health specifically methylation, glutathione, and mitochondrial functions.

Methylation turns proteins in the body on and off including DNA and RNA a function that controls gene activity.

Glutathione, a primary antioxidant, provides a defense against toxic metals in the body. Mitochondria are essentially the "factories" inside body cells that produce energy.

The research team has been developing therapies aimed at restoring or improving these functions in people with autism experiencing abnormalities.

The complete study is published in the medical journal Autism Insights, and is available online at http://la-press.com/article.php?article_id=2665

The team includes:

  • James Adams, a professor in the School for Engineering of Matter, Transport and Energy, one of ASU's Ira A. Fulton Schools of Engineering
  • Stuart Freedenfeld, physician and medical director with Stockton Family Practice, in Stockton, N.J.
  • Tapan Audhya, a biochemist with the Health Diagnostics and Research Institute, in South Amboy, N.J.
  • Kim Hamada, a registered nurse with Stockton Family Practice.

A common feature of the abnormalities the researchers are studying is that they are affected directly or indirectly by levels of specific substances produced by the body ribose and nicotinamide adenine dinucleotide, or NADH.

Use of ribose and NADH supplements have been reported to boost levels of adenosine-5'-triphosphate, or ATP a primary fuel source for the body and the brain. The supplements have also been shown to be helpful in treating chronic fatigue.

The research team explored use of ribose and NADH supplements as treatments for autism in two parallel studies using ribose and NADH.

One study investigated the effect of supplementation with NADH, an important co-factor for many enzymatic reactions in the body.

Another study investigated the effect of supplementation with ribose, a special sugar made by the body from glucose.

The studies found use of ribose and NADH supplements had similar effects, boosting levels of methylation, glutathione and ATP after only two weeks of therapy.

Levels of ribose and NADH also improved substantially, without adverse effects. After just two weeks of therapy, one child in each group was reported to have some improvement in energy level.

The biochemistry of both NADH and ribose is well-established, as well as how both affect production of ATP, glutathione and methylation. Details are provided in the article in Autism Insights.

Adams points out that both treatments use products that are available as over-the-counter nutritional supplements.

Larger and more formal studies are needed to confirm the benefits of ribose and NADH supplements, Freedenfeld says.

But "these therapies appear to be safe and effective supportive therapies for restoring methylation, glutathione and ATP to near-normal levels in the body, and are likely to help children with autism who experience problems maintaining normal functions," he says.


'/>"/>

Contact: Joe Kullman
joe.kullman@asu.edu
480-965-8122
Arizona State University
Source:Eurekalert

Related biology news :

1. Landmark study unlocks stem cell, DNA secrets to speed therapies
2. Efavirenz-based initial therapies associated with better outcomes in HIV-infected adults
3. Mechanisms of cardiovascular disease and cancer give clues to new therapies
4. Pigs and dogs can bridge gap between mice and humans in developing new therapies
5. Digital communication technology helps clear path to personalized therapies
6. Cancer-causing gene discovery suggests new therapies
7. Common gene variants increase risk of hypertension, may lead to new therapies
8. ChemoBrain: How cancer therapies can affect your mind
9. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
10. Amniotic fluid may provide new source of stem cells for future therapies
11. Publication sets guidelines across cancer therapies: Ensuring the best in patient management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/4/2017)... LAS VEGAS , Jan. 4, 2017 /PRNewswire/ ... in performance biometric sensor technology, today announced the ... Benchmark™ sensor systems, the highly-accurate biometric sensor ... ® biometric technology, experience and expertise. The ... of Benchmark designed specifically for hearables, and Benchmark ...
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   ... data sensor technology, and STMicroelectronics (NYSE: ... spectrum of electronics applications, announced today the launch ... kit for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, ...
(Date:12/15/2016)... and BADEN-BADEN, Germany , December 15, 2016 ... financial services provider, today announced an agreement with NuData Security, ... to join forces. The partnership will enable clients to focus ... compliance with local data protection regulation. ... In order to provide a ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... 2017  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), ... for operable and inoperable solid tumor cancers, announced today ... of NW Bio, will present at the Phacilitate Immunotherapy ... Hyatt Regency Hotel in Miami, Florida ... entitled "New Therapeutic Approaches – Expanding the Reach of ...
(Date:1/18/2017)... January 18, 2017 According to a new market research ... Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, Academic and Research Institutions) ... reach USD 739.9 Million by 2021 from USD 557.1 Million in 2016, growing ... ... MarketsandMarkets Logo ...
(Date:1/18/2017)... ... ... Executive search firm Slone Partners proudly supports the SCOPE ... of the clinical trials segment. Hosted in Miami, this conference brings together renowned ... , As executive talent specialists in the industries central to clinical trials, ...
(Date:1/18/2017)... ... 2017 , ... MYOLYN, which creates medical technology for people ... to the FDA, requesting clearance of the MyoCycle Home and the MyoCycle Pro ... , The submission marks a major milestone for the technology startup. MYOLYN spun ...
Breaking Biology Technology: